Stempeutics weighs Japan tie-up for stem cell therapy
This article was originally published in Scrip
Executive Summary
Japan continues to attract interest in the area of regenerative medicine. Indian firm Stempeutics Research now says it is eyeing collaboration opportunities for its stem-cell based drug, Stempeucel, initially targeted for the treatment of critical limb ischemia.
You may also be interested in...
India Clears Off-The-Shelf Stem Cell Therapy for Buerger's
Stempeutics Research has been granted limited approval to make and sell the first allogeneic cell therapy product for Buerger’s Disease in India. The stem cell therapy, which was granted orphan drug designation by the EMA last year, may hold potential in certain additional indications as well.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet